Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants With Symptoms of Common Cold

ClinicalTrials.gov ID: NCT03005067

Public ClinicalTrials.gov record NCT03005067. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Subjects With Symptoms of Common Cold

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will be conducted in adult participants with symptoms of common cold assessing if 1146A nasal spray reduces the severity of symptoms of the common cold compared to placebo. The study will also evaluate the safety of 1146A compared to placebo.

Study identification

NCT ID
NCT03005067
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
171 participants

Conditions and interventions

Conditions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 28, 2016
Primary completion
Jun 6, 2017
Completion
Jun 6, 2017
Last update posted
Jun 18, 2018

2016 – 2017

United States locations

U.S. sites
24
U.S. states
17
U.S. cities
24
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35211
GSK Investigational Site Chandler Arizona 85224
GSK Investigational Site Mesa Arizona 85206
GSK Investigational Site Vista California 92083
GSK Investigational Site Centennial Colorado 80112
GSK Investigational Site Littleton Colorado 80128
GSK Investigational Site Pinellas Park Florida 33781
GSK Investigational Site Chicago Illinois 60602
GSK Investigational Site Council Bluffs Iowa 51503
GSK Investigational Site Edina Minnesota 55435
GSK Investigational Site St Louis Missouri 63141
GSK Investigational Site Elkhorn Nebraska 68022
GSK Investigational Site Fremont Nebraska 68025
GSK Investigational Site Omaha Nebraska 68144
GSK Investigational Site Vineland New Jersey
GSK Investigational Site Akron Ohio 44311
GSK Investigational Site Cincinnati Ohio 45249
GSK Investigational Site Hatboro Pennsylvania 19040
GSK Investigational Site Anderson South Carolina 29621
GSK Investigational Site Dallas Texas 75234
GSK Investigational Site Plano Texas 75093
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Murray Utah 84123
GSK Investigational Site Bellevue Washington 98004

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03005067, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 18, 2018 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03005067 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →